USFDA grants appeal for Ardelyx's XPHOZAH
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
Cipla and Ethris partner for the development of mRNA-based therapies
All claims against the company in the litigation have now been dismissed.
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Subscribe To Our Newsletter & Stay Updated